RxDoctor Payments DataLook up a doctor →

Sachin Bahl, MD

Endocrinology, Diabetes & Metabolism · Pittsburgh, PANPI 1841377579

Payments from drug & device makers

$161,709in general payments, 2019–2025

Across 766 payments — averaging $211.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$120K
  • Boehringer Ingelheim$16K
  • Lilly USA, LLC$16K
  • AstraZeneca$1K
  • Sanofi-aventis U.S. LLC$1K
  • Novo Nordisk$1K
  • plus $6K from 46 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)7$120,067
Boehringer Ingelheim91$16,325
Lilly USA, LLC104$16,076
AstraZeneca(2 entities)30$1,273
Sanofi-aventis U.S. LLC107$1,231
Novo Nordisk99$1,143
Bayer71$818
Dexcom, Inc.35$739
Amgen36$591
Medtronic(2 entities)10$243
Amneal Pharmaceuticals LLC12$226
BD10$222
Corcept Therapeutics10$214
Merck19$213
Mannkind Corporation15$191
GSK10$187
Insulet Corporation8$144
Abbott8$133
E.r. Squibb & Sons, L.L.C.6$118
Neurocrine Biosciences, Inc.5$113
Cequr Corporation1$108
Exact Sciences4$85
Xeris Pharmaceuticals, Inc.5$83
Johnson & Johnson3$76
Ultragenyx Pharmaceutical Inc.4$70
Antares Pharma, Inc.3$68
Endo Pharmaceuticals Inc.3$62
Amarin Pharma, Inc.3$62
Grifols USA, LLC3$61
Embecta Corp.2$60
Takeda Pharmaceuticals U.S.A., Inc.4$60
Ascendis Pharma Endocrinology Inc3$57
Soleno Therapeutics, Inc.3$54
Novartis3$48
Pfizer3$48
Arbor Pharmaceuticals, Inc.3$45
Sequel Med Tech, LLC2$43
BETA Bionics, Inc.2$40
Acella Pharmaceuticals, LLC2$39
Shire North American Group Inc2$35
Kowa Pharmaceuticals America, Inc.2$31
Amphastar Pharmaceuticals, Inc.2$27
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC1$24
Halozyme Inc1$20
Aytu Biopharma, Inc.1$20
Verity Pharmaceuticals Inc.1$18
Recordati_rare_diseases_inc.1$18
Zealand Pharma US, Inc.1$18
Lifescan, Inc.1$17
Acerus Pharmaceuticals Corporation1$16
Tandem Diabetes Care, Inc.2$16
Madrigal Pharmaceuticals1$15

How this compares

$161,709 in reported general payments places this provider in the 90th percentile of 388 endocrinology, diabetes & metabolism providers in Pennsylvania.

See all endocrinology, diabetes & metabolism providers in Pennsylvania →

Medicare billing

Part B allowed, 2024
$121,358
Medicare patients
388
Services billed
1,550

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Pittsburgh

See the full list for Pennsylvania →

Where these figures come from

Is this you, or does something look wrong? →